Literature DB >> 12171682

The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum.

J H Hagman1, A M Carrozzo, E Campione, P Romanelli, S Chimenti.   

Abstract

BACKGROUND: Immunosuppressive medications such as corticosteroids and cyclosporin are the most commonly employed therapies in pyoderma gangrenosum. We describe a patient with multiple ulcers of pyoderma gangrenosum on the lower extremities in whom immunosuppressive therapy caused serious side effects and had to be discontinued but who was subsequently treated successfully with high dose intravenous immunoglobulin (IVIG).
METHODS: IVIG was given intravenously at a dose of 400 mg/kg per day for 5 consecutive days. After 1 week there was an arrest in the progression of the ulcers and a marked reduction in pain. Two weeks later clinical improvement of the ulcers was observed. Subsequently, IVIG was given at a dose of 1 g/kg per day for 2 consecutive days.
RESULTS: The treatment induced a dramatic clinical improvement of one ulcer and healing of the others. Side effects were minimal and well tolerated, and consisted of chills and a slight fever, which resolved with the administration of acetaminophen.
CONCLUSION: We feel that IVIG can be used in patients with pyoderma gangrenosum in whom conventional therapies are ineffective or produce serious side effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12171682     DOI: 10.1080/095466301750163527

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  7 in total

Review 1.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

Review 2.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

3.  Violaceous-rimmed ulcers.

Authors:  Cindy Berthelot; Jennifer Clay Cather
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-04

Review 4.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

Review 5.  [Pyoderma gangrenosum].

Authors:  K Herberger
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

Review 6.  Pyoderma gangrenosum treated with high-dose intravenous immunoglobulins: Two cases and review of the literature.

Authors:  Nicolas Meyer; Valérie Ferraro; Marie-Henriette Mignard; Henri Adamski; Jacqueline Chevrant-Breton
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

7.  Intravenous immunoglobulin as salvage therapy in refractory pyoderma gangrenosum: report of a case and review of the literature.

Authors:  John Cafardi; Naveed Sami
Journal:  Case Rep Dermatol       Date:  2014-10-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.